Roadmap for Achieving Universal Antiretroviral Treatment.

IF 11.2 1区 医学 Q1 PHARMACOLOGY & PHARMACY Annual review of pharmacology and toxicology Pub Date : 2023-01-20 DOI:10.1146/annurev-pharmtox-052020-094321
Simiso Sokhela, Samanta Lalla-Edward, Mark J Siedner, Mohammed Majam, Willem Daniel Francois Venter
{"title":"Roadmap for Achieving Universal Antiretroviral Treatment.","authors":"Simiso Sokhela, Samanta Lalla-Edward, Mark J Siedner, Mohammed Majam, Willem Daniel Francois Venter","doi":"10.1146/annurev-pharmtox-052020-094321","DOIUrl":null,"url":null,"abstract":"<p><p>Modern antiretroviral therapy safely, potently, and durably suppresses human immunodeficiency virus (HIV) that, if left untreated, predictably causes acquired immunodeficiency syndrome (AIDS), which has been responsible for tens of millions of deaths globally since it was described in 1981. In one of the most extraordinary medical success stories in modern times, a combination of pioneering basic science, innovative drug development, and ambitious public health programming resulted in access to lifesaving, safe drugs, taken as an oral tablet daily, for most of the world. However, substantial challenges remain in the fields of prevention, timely access to diagnosis, and treatment, especially in pediatric and adolescent patients. As HIV-positive adults age, treating their comorbidities will require understanding the course of different chronic diseases complicated by HIV-related and antiretroviral toxicities and finding potential treatments. Finally, new long-acting antiretrovirals on the horizon promise exciting new options in both the prevention and treatment fields.</p>","PeriodicalId":8057,"journal":{"name":"Annual review of pharmacology and toxicology","volume":null,"pages":null},"PeriodicalIF":11.2000,"publicationDate":"2023-01-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10807407/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Annual review of pharmacology and toxicology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1146/annurev-pharmtox-052020-094321","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

Abstract

Modern antiretroviral therapy safely, potently, and durably suppresses human immunodeficiency virus (HIV) that, if left untreated, predictably causes acquired immunodeficiency syndrome (AIDS), which has been responsible for tens of millions of deaths globally since it was described in 1981. In one of the most extraordinary medical success stories in modern times, a combination of pioneering basic science, innovative drug development, and ambitious public health programming resulted in access to lifesaving, safe drugs, taken as an oral tablet daily, for most of the world. However, substantial challenges remain in the fields of prevention, timely access to diagnosis, and treatment, especially in pediatric and adolescent patients. As HIV-positive adults age, treating their comorbidities will require understanding the course of different chronic diseases complicated by HIV-related and antiretroviral toxicities and finding potential treatments. Finally, new long-acting antiretrovirals on the horizon promise exciting new options in both the prevention and treatment fields.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
实现普及抗逆转录病毒治疗的路线图。
现代抗逆转录病毒疗法能够安全、有效、持久地抑制人体免疫缺陷病毒(HIV),如果不及时治疗,就会导致获得性免疫缺陷综合征(艾滋病),自 1981 年艾滋病被描述以来,全球已有数千万人死于艾滋病。在现代最非凡的医学成功故事中,开创性的基础科学、创新性的药物开发和雄心勃勃的公共卫生计划相结合,使世界上大多数人都能获得救命的安全药物,每天口服一片。然而,在预防、及时诊断和治疗方面,尤其是在儿童和青少年患者中,仍然存在巨大的挑战。随着 HIV 阳性成人患者年龄的增长,治疗他们的合并症需要了解因 HIV 相关和抗逆转录病毒毒性而复杂化的不同慢性疾病的病程,并找到潜在的治疗方法。最后,即将问世的新型长效抗逆转录病毒药物为预防和治疗领域带来了令人兴奋的新选择。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
27.80
自引率
0.00%
发文量
53
期刊介绍: Since 1961, the Annual Review of Pharmacology and Toxicology has been a comprehensive resource covering significant developments in pharmacology and toxicology. The journal encompasses various aspects, including receptors, transporters, enzymes, chemical agents, drug development science, and systems like the immune, nervous, gastrointestinal, cardiovascular, endocrine, and pulmonary systems. Special topics are also featured in this annual review.
期刊最新文献
Treating Sickle Cell Disease: Gene Therapy Approaches Weight Loss Blockbuster Development: A Role for Unimolecular Polypharmacology Gut Microbiota–Related Biomarkers in Immuno-Oncology Immunoregulation of Liver Fibrosis: New Opportunities for Antifibrotic Therapy Opportunities for Microphysiological Systems in Toxicity Testing of New Drug Modalities.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1